The University of Chicago Header Logo

Connection

Mark W. Lingen to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Mark W. Lingen has written about Xenograft Model Antitumor Assays.
Mark W. Lingen
Connection Strength
0.103
Xenograft Model Antitumor Assays
  1. Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC. Oncotarget. 2016 Mar 22; 7(12):14029-47.
    View in: PubMed
    Score: 0.031
  2. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
    View in: PubMed
    Score: 0.029
  3. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
    View in: PubMed
    Score: 0.024
  4. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.